T he combination of ADs and brief psychotherapies is widely used in the treatment of MDD and has been proven more efficacious than monotherapy with either ADs or psychotherapy in improving depressive symptoms and social functioning. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Of the choices of psychotherapy, CT and IPT are 2 timelimited treatments that were specifically proposed for major depression and extensively studied in trials of monotherapy or combined therapy. 1, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Major depression is commonly associated with personality disorders. In particular, MDD is the most common Axis I comorbidity in populations with BPD, [29] [30] [31] [32] [33] [34] [35] [36] a serious and persistent mental disorder characterized by a pervasive pattern of instability of interpersonal relationships, affects, and self-image, as well as marked impulsivity that appears in a variety of contexts. 37 Clinical data and APA treatment guidelines for major depression indicate that providing combined therapy is particularly recommended in patients with concomitant personality disorders. 18, [38] [39] [40] Kool and colleagues 41 compared the efficacy of combined therapy with ADs and short psychodynamic supportive psychotherapy and monotherapy with ADs in 72 patients with MDD. They concluded that depressed patients with comorbid personality disorder appeared to benefit most from combined therapy. The results were most striking for cluster C disorders. A recent study of our group 42 included 32 BPD patients who present a major depressive episode (not bipolar and not psychotic). A combination of fluoxetine and IPT was found more efficacious than fluoxetine monotherapy after 24 weeks, on measures of depressive symptoms, subjective QOL, and interpersonal problems. Although different psychotherapies have been chosen for combined treatment, their effects on depressed patients with concomitant personality disorders have not been compared. In particular, we have no data to determine if combined treatments with different psychotherapies can induce specific changes in patients with MDD and BPD.
This study compares the association of an SSRI with CT or IPT in treating a group of patients who presented a major depressive episode with concomitant BPD.
Method
The study participants were selected from patients attending the Service for Personality Disorders of the Unit of Psychiatry, Department of Neurosciences, University of Turin, from April to December 2005.
We included consecutive outpatients who received a DSM-IV-TR 37 diagnosis of BPD and then met criteria for a major depressive episode (that is, mild to moderate).
Diagnoses were made by an expert clinician and were confirmed using the Structured Clinical Interview for DSM-IV Axis I and II disorders. 43, 44 We excluded individuals with a lifetime diagnosis of delirium, dementia, amnestic or other cognitive disorders, schizophrenia or other psychotic disorders, and patients whose major depressive episode was an expression of bipolar disorder.
Limitations
· Sample size was relatively small and results need to be replicated. · Study lacked a long-term follow-up to assess if clinical improvement is maintained after the end of treatment. · Assessment instruments did not include a specific scale for measuring BPD-related symptoms. Exclusion criteria also considered a current diagnosis of substance abuse disorder and whether an individual was treated with psychotropic drugs or psychotherapy during the 2 months prior to the study. Female patients of child-bearing age were excluded if they were not using an adequate method of birth control (according to the judgment of the clinician).
Abbreviations used in this article
Written informed consent was obtained from all patients prior to their participation. We had ethics board approval and followed Declaration of Helsinki guidelines.
Patients included in the study were randomized using the web program Research Randomizer v3.0 (Urbaniak & Plous, Social Psychology Network, 2007) and were assigned to one of 2 treatment groups of combined therapy: IPT plus pharmacotherapy, or CT plus pharmacotherapy. Patients underwent their respective treatments for 24 weeks.
All 32 patients included in the study received 20 to 40 mg of fluoxetine daily. Initially, fluoxetine was prescribed at a fixed dosage of 20 mg daily with the opportunity to increase the dosage to 40 mg daily beginning in week 2, depending on clinical judgment. A psychiatrist provided pharmacotherapy. He was blind to which type of psychotherapy the patients were receiving. Each patient was given 7 appointments, the first 2 fortnightly and the last 5 monthly.
Sixteen patients received fluoxetine plus IPT, the remaining 16 received fluoxetine plus CT. IPT consisted of weekly sessions lasting 1 hour and was conducted referring to the IPT of depression manual. 45 Patients in the IPT group were treated by a psychotherapist who was not the psychiatrist prescribing medication and who had at least 5 years of experience practising IPT. CT consisted of weekly 1-hour sessions and were conducted referring to the manuals of cognitive therapy of depression. 46, 47 Patients in the CT group were treated by a psychotherapist who was neither the psychiatrist prescribing medication nor the psychotherapist providing IPT, and who had at least 5 years of experience practising CT. Both psychotherapists received supervision during the treatment to assess their adherence to the psychotherapy manuals. The pharmacotherapy and both psychotherapies started simultaneously.
All patients were repeatedly assessed (that is, at baseline, week 12, and week 24) with the following measures: a semistructured interview to assess demographic and clinical characteristics; the Severity and Improvement items of the CGI scale to assess the level of global symptomatology 48 ; the HDRS and HARS 49, 50 ; the revised BDI-II, a self-report instrument developed to assess the severity of depression according to Beck's cognitive theories 51 ; the SOFAS, a self-report scale that assesses the social and occupational level of functioning 52 ; the SAT-P, 53 a self-administered questionnaire consisting of 32 scales that provides a satisfaction profile in daily life and can be considered as an indicator of subjective QOL. The SAT-P considers 5 different factors: psychological functioning; physical functioning; work; sleep, food, and free time; and social functioning. This questionnaire allows for analysis of patients' perception of their level of functioning and treatment benefits. Patients were also assessed with IIP-64, 54 a self-report inventory to identify problematic areas in interpersonal relationships. This inventory assesses the severity of interpersonal problems in 8 domains: domineering or controlling; vindictive or self-centred; cold and distant; socially inhibited; nonassertive; overly accommodating; selfsacrificing; and intrusive or needy. The IIP-64 has been widely used to assess psychotherapy outcome. [55] [56] [57] [58] The assessments were performed by an investigator who was blind to the treatment methods. Remission was defined by a decreased HDRS score ($ 40%), with a final score of # 8, and a score of 1 (very much improved) or 2 (much improved) on the Improvement item of the CGI.
We performed statistical analyses using the software system SPSS, version 13.0 (SPSS Inc, Chicago, Illinois, 2004). Only those patients who completed the study were included in the analysis. We used Student t test and Fisher's exact test to compare demographic and clinical characteristics (that is, age, sex, the Severity item of the CGI, HDRS and HARS scores, and BDI-II scores) at baseline. The Student t test was used to compare mean daily doses of fluoxetine in the 2 subgroups and Fisher's exact test was performed to compare the number of patients who achieved remission. We used the univariate GLM to calculate the effects of 2 factors (duration and type of treatment) on each assessment scale score. P values were considered significant when P £ 0.05.
Results
Initially, there were 32 patients enrolled in the study. At intake, there were no significant differences between the 2 treatment groups concerning age, sex, the Severity item of the CGI, HDRS and HARS scores, and BDI-II scores. Owing to noncompliance, 6 patients discontinued treatment during the first 3 weeks. Of these subjects, 2 were in the IPT group, and 4 were in the CT group. We performed statistical analyses of outcome measures on the 26 patients (that is, 14 patients in the IPT group and 12 patients in the CT group) who completed the 24 weeks of treatment. The sample had a mean age of 30.55, SD 5.75 years. The ratio of men to women was 7 to 19 (2.71).
The mean dosages of fluoxetine were equivalent in the 2 groups: 32.86 mg daily, SD 9.95 mg, in the group treated with IPT and 30.00 mg daily, SD 10.45 mg, in the group treated with CT (P = 0.48). At the end point, 71.43% (n = 10) of the IPT treated patients and 66.67% (n = 8) of CT treated patients achieved remission. Statistical comparison with the Fisher's exact test did not show a significant difference (P = 0.56).
Results of the univariate GLM performed on the Severity item of the CGI, HDRS, HARS, BDI-II, and SOFAS results are presented in Table 1 . On each scale, we found that the time factor had a significant effect (P < 0.005). The treatment factor showed a significant effect (P = 0.007) only on the HARS, which indicates a higher score change in the subgroup receiving fluoxetine and CT.
In Table 2 , the results of the GLM applied to the 5 factors of the SAT-P are presented. There was a significant change in 4 of the 5 factors related to the length of treatments, that is, psychological functioning; physical functioning; sleep, food, and free time; and social functioning (P < 0.007). We found that the treatment factor had a significant effect (P = 0.02) on the psychological functioning factor: combined therapy with CT was more effective. The treatment factor also had a significant effect (P = 0.02) on the social functioning factor: the efficacy of combined therapy with IPT was greater.
Results of the univariate GLM applied to the 8 domains of the IIP-64 are described in Table 3 . Findings differ depending on which domain is considered. Neither time nor treatment factors had a significant effect on any of the following 5 domains: cold or distant; socially inhibited; nonassertive; overly accommodating; and self-sacrificing. The time factor had a significant effect (P < 0.001) on the vindictive or selfcentred domain. Both the time (P < 0.001) and the treatment factor (P < 0.01) had a significant effect on the domineering or controlling and intrusive or needy domains. These results indicate that combined therapy with IPT has more of an impact on these areas than combined therapy with CT.
Discussion
Our study compared the efficacy of 2 types of psychotherapy (that is, IPT or CT) associated with a SSRI (that is, fluoxetine) in the treatment of patients with a major depressive episode and preexisting BPD. We chose fluoxetine because it is a widely used AD [59] [60] [61] and it is also recommended by APA treatment guidelines for BPD. 62 Our patients were treated with IPT or CT because these approaches have been initially proposed and extensively studied for the treatment of MDD. 1, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] In addition, they are now considered among the effective psychotherapies for BPD. 42, 60, [63] [64] [65] [66] [67] [68] [69] The combination of pharmacotherapy and psychotherapy is recommended by APA guidelines both for treatment of MDD and BPD. 18, [60] [61] [62] In particular, combined therapy is preferable to monotherapy when interpersonal problems or personality disorders are associated with major depression. 18, [38] [39] [40] [41] [42] [70] [71] [72] [73] [74] [75] In our study, the 2 treatment options did not significantly differ in rates of remission, improvement of global psychopathology, social and occupational functioning, and reduction of depressive symptoms. These findings agree with other research that found that combined therapy with IPT or CT are efficacious in depressive disorders. 14, 20, [25] [26] [27] Significant differences between the 2 subgroups of our study were found in measures of anxious symptoms, factors related to Concerning the efficacy of combined therapy with CT, our results showed that it was significantly superior to combined therapy with IPT in reducing anxious symptoms as measured by the HARS. These data appear concordant with Gunderson's opinion that CT well-structured techniques (that is, role-playing, instructions, homework, and mental exercises) are useful instruments in reducing anxious symptoms in BPD patients. 76 Moreover, CT is significantly superior to IPT in improving the psychological functioning as measured by the SAT-P scale for QOL. Subjective perception of psychological functioning deals with self-esteem, psychological autonomy, problem-solving ability, emotional stability, self-control, and sense of identity. This finding confirms an open clinical trial of CT in depressed patients with BPD, reporting significant reduction in depressive symptoms and improvement in dysfunctional beliefs concerning selfperception, dependency, helplessness, and emotional control. 65 If we consider the efficacy of combined therapy with IPT, it was found significantly superior to combined therapy with CT in improving the social functioning as measured by the SAT-P, and the 2 domains domineering or controlling and intrusive or needy as measured by the IIP-64 scale for interpersonal problems. Subjective experience of social functioning deals with the quality of social relations in different contexts in each patient's life. According to some research, 68, 71, 76, 77 social functioning is more compromised in depressed patients with concomitant BPD than in depressed patients who do not have personality disorders. Difficulties in handling relationships with family members, colleagues, and friends provide appropriate targets for the IPT treatment, and change of dysfunctional interpersonal patterns can improve the patient's QOL. The 2 domains domineering or controlling and intrusive or needy of the IIP-64 refer to areas of interpersonal problems that often represent a core feature of patients with BPD. These patients have a powerful need to feel engaged with other people and impose their control, because they cannot tolerate the fear of being abandoned. An improvement in these areas indicates that patients have developed more functional models for handling interpersonal relationships, reducing their intrusive and controlling attitudes. A reliable comparison of our results with published research is not possible.
Although IPT and CT have both been widely studied in the treatment of major depression and are considered promising options for dealing with patients with BPD, systematic data on their use in combined therapy of patients with concomitant BPD and major depression are not available for CT and limited for IPT. The group treated by Brown included 15 patients (52%) who received various medications when they entered the trial with CT (9 received SSRIs). However, the study was not focused on efficacy of combined therapy and did not compare combined therapy with pharmacotherapy or psychotherapy. A previous investigation of our group 42 found that the combination of IPT and fluoxetine was more efficacious than pharmacotherapy alone in a group of 32 depressed patients with BPD when considering measures of depressive symptoms, QOL, and interpersonal problems.
In summary, data from the present study indicate that the combination of fluoxetine with either CT or IPT is efficacious in treating major depression in patients with BPD during a 6-month period. Differences between the 2 treatment modalities concern specific effects on subjective QOL and interpersonal problems, which appear to reflect the different goals of the 2 psychotherapies focused on cognitive and interpersonal issues.
A major limitation of the present study is the lack of long-term follow-up to assess whether clinical and functional improvements are maintained after the end of the trial. We are currently collecting and analyzing data at 6 and 12 months after end-point. A second limitation is that assessment instruments did not include a specific scale for measuring BPD-related symptoms. The reason is that the main object of the study was to compare the effects of 2 combined therapies on major depression with concomitant BPD. Therefore, our data concerned improvement of depression and functional impairment; however, we did not consider what happened to BPD dysfunctional traits and related symptoms. Another limitation is that an intention-to-treat analysis was not carried out, because it could have affected the results.
Further investigations are required on larger samples to replicate these initial findings and confirm that combined therapies with CT or IPT produce specific effects on the clinical picture and functional profile of depressed patients with BPD.
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